Resurrect Bio, a London-based agricultural biotechnology company, has closed the initial tranche of its Series A at $8.1 million. Corteva led the round through its Corteva Catalyst platform, joined by Calculus Capital, Pymwymic, UKI2S, SynBioVen and AgFunder.
The company uses gene editing to restore disease resistance traits that pathogens have suppressed in crops. Its platform combines FloraFold AI computational biology with high-throughput plant screening to identify dormant resistance genes. These are then reactivated through small, targeted changes to native plant DNA. The result is crops better equipped to defend themselves, without the lengthy timelines of conventional breeding.
CEO Dr. Cian Duggan said the funding positions Resurrect Bio to scale its platform and deliver multiple resistance traits to seed industry partners. “We’re thrilled to have secured this investment from partners who share our vision of delivering durable disease resistance to farmers,” he said.
Tom Greene, senior director at Corteva and global leader for Corteva Catalyst, said the investment reflects the firm’s broader push to find sustainable crop protection tools. He added that the partnership would help explore next-generation gene editing capabilities tied to Corteva’s germplasm portfolio.
The fresh capital will accelerate Resurrect Bio’s trait discovery platform and push several resistance products closer to commercial partnerships. Plant diseases are a growing threat to global food security. The company is betting that reactivating a plant’s own genetic defenses offers a more durable solution than existing options.
The post Resurrect Bio lands $8.1M to bring disease-resistant crops to farmers appeared first on World Bio Market Insights.
